Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle These data suggest that pretreatment evaluation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results